These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2445283)

  • 41. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
    Fabrizi F; Dixit V; Martin P; Messa P
    J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influenza B in transplant patients.
    Aschan J; Ringdén O; Ljungman P; Andersson J; Lewensohn-Fuchs I; Forsgren M
    Scand J Infect Dis; 1989; 21(3):349-50. PubMed ID: 2667101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.
    Bodeau S; Lemouel JP; Diouf M; Duverlie G; Nguyen-Khac E; Brochot E
    J Med Virol; 2017 Jun; 89(6):1033-1039. PubMed ID: 27805268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
    Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
    Hepatology; 2011 May; 53(5):1774-5; author reply 1775-6. PubMed ID: 21520186
    [No Abstract]   [Full Text] [Related]  

  • 46. Hematologic adverse effects and efficacy monitoring in chronic Hepatitis C patients treated with interferon and ribavirin combination therapy.
    Rafique G; Bukhsh A; Gul A; Khiljee S; Ashraf M; Omer MO
    Pak J Pharm Sci; 2017 Jan; 30(1):11-16. PubMed ID: 28603106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy.
    Gowen BB; Westover JB; Sefing EJ; Van Wettere AJ; Bailey KW; Wandersee L; Komeno T; Furuta Y
    Antiviral Res; 2017 Sep; 145():131-135. PubMed ID: 28780425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ribavirin.
    Isaacs D
    Pediatrics; 1987 Feb; 79(2):289-91. PubMed ID: 3808806
    [No Abstract]   [Full Text] [Related]  

  • 49. A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
    Ide T; Okamura T; Kumashiro R; Koga Y; Hino T; Hisamochi A; Ogata K; Tanaka K; Kuwahara R; Seki R; Sata M
    Int J Mol Med; 2003 Jun; 11(6):729-32. PubMed ID: 12736713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ribavirin: an antiviral agent with promise.
    Mack JE
    Pediatr Nurs; 1988; 14(3):220-1. PubMed ID: 3380572
    [No Abstract]   [Full Text] [Related]  

  • 51. Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat.
    Gruber WC; Wilson SZ; Throop BJ; Wyde PR
    Pediatr Res; 1987 Mar; 21(3):270-4. PubMed ID: 3550674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome.
    Huggins JW; Hsiang CM; Cosgriff TM; Guang MY; Smith JI; Wu ZO; LeDuc JW; Zheng ZM; Meegan JM; Wang QN
    J Infect Dis; 1991 Dec; 164(6):1119-27. PubMed ID: 1683355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ribavirin therapy for lassa fever.
    Snell N
    Practitioner; 1988 Apr; 232(1447):432. PubMed ID: 3249720
    [No Abstract]   [Full Text] [Related]  

  • 54. Ribavirin therapy for Hantaan virus infection in suckling mice.
    Huggins JW; Kim GR; Brand OM; McKee KT
    J Infect Dis; 1986 Mar; 153(3):489-97. PubMed ID: 2869089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.
    Calanca LN; Fehr T; Jochum W; Fischer-Vetter J; Müllhaupt B; Wüthrich RP; Ambühl PM
    J Clin Virol; 2007 May; 39(1):54-8. PubMed ID: 17409018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection.
    Bierman SM; Kirkpatrick W; Fernandez H
    Chemotherapy; 1981; 27(2):139-45. PubMed ID: 7009087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ribavirin. Ambivalence about an antiviral agent.
    Ray CG
    Am J Dis Child; 1988 May; 142(5):488-9. PubMed ID: 3358387
    [No Abstract]   [Full Text] [Related]  

  • 58. [Severe bone marrow aplasia due to triple therapy for hepatitis C virus infection: Apropos of a case].
    Bautista Galán C; Serrato AR; Albandea Moreno C; Ruiz Arredondo J
    Gastroenterol Hepatol; 2015 Nov; 38(9):542-3. PubMed ID: 25835261
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.
    Pham HP; Féray C; Samuel D; Gigou M; Azoulay D; Paradis V; Ducret F; Charpentier B; Debuire B; Lemoine A
    Kidney Int; 1998 Oct; 54(4):1311-9. PubMed ID: 9767549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ribavirin.
    Conner CS
    Drug Intell Clin Pharm; 1984 Feb; 18(2):137-8. PubMed ID: 6697874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.